Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 13, 653 (2007)
Published online: 31 May 2007 | doi:10.1038/nm0607-653b
Is it possible to make a Cox-2 inhibitor that's safe?
Abstract
On 27 April, the US Food and Drug Administration rejected Merck's application for Arcoxia, a Cox-2-targeting painkiller widely seen as the successor to the ill-fated Vioxx. The fate of Vioxx, Arcoxia's rejection—and the dearth of other effective painkillers in the market—begs the question...
Steve NissenChairman, Department of Cardiovascular Medicine Cleveland Clinic Foundation
To read this story in full you will need to login or make a payment (see right).
